LAUSR

Background Exercise therapy is part of the recommendation for the treatment of chronic non-specific low back pain (LBP). Functional exercise may be an alternative for the treatment, no studies assessing its effectiveness were found. Objectives To assess the effectiveness of the functional exercise program for pain, functional capacity, general health, kinesiophobia and perceived exertion in adults with chronic nonspecific LBP. Methods A randomized controlled clinical trial with intention-to-treat analysis and 24-week follow-up was performed. Eighty-four patients were randomly assigned to an experimental group (EG) or control group (CG). The EG participated in the functional exercises program performed twice a week for twelve weeks. The functional exercise program was composed by global exercise that worked the group of muscles of the trunk and lower and upper limbs with progression every 4 weeks. The two groups received an informative class on the disease and were advised to use analgesic if necessary. Primary outcome was LBP measured by numeric rating scale (NRS). Secondary outcomes included was functional capacity by Oswestry and Roland Morris questionnaires, 6-minute walk and TUG tests, kinesiophobia (FABQ), general health (SF-36), perceived exertion (BORG). Evaluations were performed at baseline, after 6, 12 (end of intervention) and 24 weeks by a blind evaluator. Results The groups were homogeneous for all parameters at baseline. Compared with the CG, the EG statistically improved pain, functional capacity, kinesiophobia, some domains of general health and peceived exertion - Table 1. Conclusion The functional exercise program was effective to improve pain, functional capacity, kinesiophobia, general health and percepived exertion in adults with chronic nonspecific LBP. References [1] Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis and Rheumatism. 2012. [2] Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, et al. What low back pain is and why we need to pay attention. The Lancet. 2018.Abstract OP0273HPR Table 1 Between-groups evaluations T0 T6 T12 T24 p Value(GLM) EG CG EG CG EG CG EG CG NSR 6.2 (1.3) 6.0 (1.7) 3.1 (1.8) 5.5 (1.7) 2.3 (1.9) 5.5 (1.8) 2.3 (1.8) 5.5 (1.6) <0.001* ODI 20.7 (10.8) 25.5 (11.3) 12.0 (7.0) 22.1 (10.3) 9.5 (6.3) 22.5 (10.5) 8.9 (6.4) 22.8 (10.9) <0.001* RMDQ 6.9 (5.0) 8.4 (5.3) 4.1 (3.3) 7.6 (4.7) 2.8 (2.6) 7.3 (4.7) 2.6 (2.4) 8.1 (5.2) <0.001* TUG 8.3 (1.1) 8.7 (2.6) 8.27 (1.94) 8.69 (1.90) 7.84 (1.08) 8.99 (2.14) 7.86 (0.83) 9.08 (2.49) 0.005* FABQ work 18.6 (15.7) 17.6 (12.0) 12.4 (9.0) 16.8 (12.0) 10.5 (9.3) 16.6 (11.1) 7.5 (7.4) 17.6 (11.4) <0.001* FABQ phys 11.9 (6.2) 13.0 (6.3) 7.1 (6.5) 13.0 (7.1) 7.0 (6.0) 13.2 (7.3) 6.9 (6.1) 13.0 (7.5) <0.001* SF-36 Physical functioning 66.1 (21.3) 60.1 (25.7) 77.7 (16.5) 61.8 (24.2) 83.8 (13.8) 58.2 (26.4) 82.4 (14.3) 60.1 (26.7) <0.001* Role physical 55.4 (40.8) 45.8 (39.8) 78.1 (31.2) 48.8 (38.2) 86.3 (24.8) 49.4 (42.9) 87.7 (17.6) 47.0 (39.9) 0.046* Bodily pain 45.8 (17.0) 40.0 (14.9) 65.1 (19.8) 55.7 (20.4) 76.7 (16.0) 62.0 (21.7) 66.7 (21.6) 61.1 (24.7) <0.001* General health 64.8 (21.3) 62.0 (20.1) 68.3 (18.9) 65.6 (17.2) 77.2 (15.6) 62.0 (17.2) 76.0 (15.2) 62.0 (17.4) <0.001* Vitality 46.4 (19.1) 48.0 (22.3) 58.8 (17.2) 46.5 (21.2) 64.1 (15.4) 48.6 (18.9) 62.7 (17.6) 47.6 (19.9) <0.001* Social functioning 68.6 (24.7) 65.7 (41.8) 80.2 (18.6) 64.8 (25.0) 87.5 (17.0) 69.6 (26.9) 87.4 (17.1) 68.3 (27.1) <0.001* Role emotional 55.4 (41.5) 61.7 (41.8) 72.1 (36.8) 55.5 (42.1) 82.4 (29.8) 56.3 (46.3) 82.2 (27.0) 64.2 (43.2) <0.001* Borg (0-10) 2.4 (0.9) 2.4 (1.5) 2.17 (1.06) 2.38 (1.01) 1.9 (0.76) 2.60 (1.40) 1.88 (0.77) 2.62 (1.96) 0.012* Data expressed as mean (standard deviation); GLM, Generalized Linear Models; *Statistically significant p value (<0,05). Disclosure of Interests None declared